GKOS insider trading
NYSE HealthcareGLAUKOS Corp — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About GLAUKOS Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Company website: www.glaukos.com
GKOS insider activity at a glance
FilingIQ has scored 1,165 insider transactions for GKOS since Jun 24, 2015. The most recent filing in our index is dated May 11, 2026.
Across the full history, 3 open-market purchases
and 354 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on GKOS insider trades is 61.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest GKOS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading GKOS
13F funds holding GKOS
Frequently asked
- How many insider trades does FilingIQ track for GKOS?
- FilingIQ tracks 1,165 Form 4 insider transactions for GKOS (GLAUKOS Corp), covering filings from Jun 24, 2015 onwards. 72 of those were filed in the last 90 days.
- Are GKOS insiders net buyers or net sellers?
- Across the full Form 4 history for GKOS, 3 transactions (0%) were open-market purchases and 354 (30%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does GKOS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is GKOS in?
- GLAUKOS Corp (GKOS) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $7.01B.
Methodology & sources
Every GKOS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.